/360_F_358094748_shwLUwwLKKlF3QqN6lh9ejwU2MAelz2T.jpg)
By Sacred Leaves Global Medical News | July 2025
Semaglutide and tirzepatide continue to attract media attention as research and real-world data highlight their broader health effects, evolving usage patterns, and clinical advantages. Experts are analyzing their profound impact beyond weight loss, including hormonal changes and national market trends.
A study presented at ENDO 2025 by Dr. Shellsea Portillo Canales showed that GLP‑1 agonists—semaglutide, dulaglutide, and tirzepatide—significantly improved testosterone levels in obese men. Normal testosterone increased from 53% to 77% over 18 months, correlating with weight reduction The Scottish Sun+15Reuters+15Gastroenterology Advisor+15EurekAlert!+2New England Journal of Medicine+2The Scottish Sun+2Lilly Investor Relations.
In India, these drugs now account for 75% of the anti-obesity market. Experts warn of misuse, particularly by non-obese individuals seeking quick cosmetic results, prompting calls for stricter prescribing protocols The Economic Times.
Phase IIIb SURMOUNT‑5 and NEJM‑published head-to-head trials show tirzepatide achieved 20.2% body weight reduction versus 13.7% with semaglutide after 72 weeks The Scottish Sun+15People.com+15Applied Clinical Trials+15.
A Cleveland Clinic study comparing trial outcomes to clinical practice found real-world patients lost significantly less weight—average ~8.7% in a year—due to lower doses and discontinuation Cleveland Clinic+1The Scottish Sun+1.
Eli Lilly captured a 60% market share with tirzepatide. The company is now developing an oral GLP‑1/GIP pill—Orforglipron—for 2026, aimed at improving convenience and affordability tctmd.com+15Business Insider+15Barron's+15.
Ongoing research will explore cardiovascular, cognitive, and hormonal outcomes. Healthcare systems are also refining usage guidelines, focusing on long-term support and the integration of lifestyle interventions alongside medication.
Both drugs mark a major shift in chronic disease management. While tirzepatide leads in efficacy, achieving optimal outcomes depends on consistent use, physician guidance, and holistic care.
Sources: